CapsoVision, Inc
corporate_fare Company Profile
CapsoVision, Inc (NASDAQ:CV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for CV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CV spans 10-Q, 4, 8-K, 424B5.
Recent high-impact activity:
- CapsoVision Misses Q3 Estimates With 15-Cent Loss, Revenue Flat at $3.57M
- CapsoVision 10-Q Flags Going Concern, Unremediated Material Weaknesses
- CapsoVision Wins FDA Clearance for AI-Powered Lesion Detection Tool
- 10% Owner Eliyahou Harari Buys $10M of CapsoVision at $5.69
- 10% Owner Shen Ching Hang Buys $5M of CapsoVision Stock at $5.69
Financial Snapshot
Short Interest & Short Volume
14.33 days to coverFINRA reported short interest of 1,951,383 shares in CV as of the October 30, 2026 settlement, a 10.6% decrease from the prior period — about 14.3 days to cover at its recent average daily volume. On November 20, 2026, 88.7% of CV volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CV, detected from its recent SEC filings · based on capital-structure filings through 2026-09-18.
Registered Direct Offering Priced · Insider Participation
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →